Navigation Links
Preliminary report on antidepressants published
Date:6/10/2009

On 10 June 2009, the Institute for Quality and Efficiency in Health Care (IQWiG) presented the preliminary results of its benefit assessment of certain newer antidepressants. The project commissioned by the Federal Joint Committee (G-BA) is concerned with assessing the benefit of three agents, reboxetine, mirtazapine and bupropion XL in adult patients with depression, according to the German drug approval status. Interested parties and institutions may submit written comments on the preliminary report up until 9 July.

Reboxetine: no proof of benefit

The assessment produced different results for the three agents. According to a literature search performed by the Institute, reboxetine (manufacturer: Pfizer) was tested in at least 16 trials on approximately 4600 patients with depression. However, the Institute only had access to data on approximately 1600 of these patients. If the unpublished data are not included, there is a high risk of incorrectly estimating the benefit and harm of this agent. IQWiG has therefore come to the preliminary conclusion that no proof of benefit from treatment with reboxetine can be deduced from the data currently available.

Mirtazapine: results must be viewed with reservation

In the search for trials on mirtazapine (Essex Pharma), it was found that this agent had been tested in at least 31 trials that could be potentially relevant to the report. However, the Institute only had access to 27 evaluable trials. As it is also possible in this case that the results of the assessment may change if all data became available, all results presented by the Institute must be viewed with reservation.

In numerous comparisons with other antidepressants, mirtazapine showed no proof of superiority. Only when compared to placebo was there proof that in acute treatment more patients experienced an improvement of depression when they were treated with mirtazapine. However, the prognosis for a full recovery was no better in the mirtazapine group than in the placebo group. In addition, it was shown that patients treated with mirtazapine discontinue treatment more often due to side effects (adverse events) than patients treated with placebo or with some of the other antidepressants.

Bupropion: proof of benefit

The search identified 6 trials on bupropion XL (up to 300 mg/d) and the Institute was given access to the complete clinical study reports by the manufacturer, GlaxoSmithKline. There was proof of benefit for this agent compared to placebo in acute therapy and in the prevention of relapse into seasonal affective disorder, while on the other hand the data provided no indications of harm. The only antidepressant that was compared with bupropion XL in trials was venlafaxine XR. Bupropion XL showed inferiority to venlafaxine XR in acute therapy. Further information can be found in the executive summary of the preliminary report (see below).

Unpublished data contain the potential for deception

If not all available study data are available, this can lead to a strongly biased assessment. This potential for deception is of fundamental importance to all researchers who systematically assess drugs and other medical technologies. The experience of the Institute shows that voluntary self-commitment cannot be relied upon. The Institute therefore considers it an urgent necessity to make it compulsory by law for study sponsors to register clinical trials before commencement and publish the results soon after study completion. IQWiG's position is described in a second press release.


'/>"/>

Contact: Dr. Anna Sabine Ernst
anna-sabine.ernst@iqwig.de
049-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
2. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
3. Air Methods Preliminary 1st Qtr. Results Exceed Expectations
4. Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
5. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
6. Cynosure Announces Preliminary Financial Results for the First Quarter of 2009
7. National All Schedules Prescription Electronic Reporting (NASPER) Bill Receives Preliminary Funding
8. NBTY to Webcast Presentation at B. Riley & Co. Annual Las Vegas Institutional Investor Conference; Announces Preliminary Unaudited Net Sales Results for February 2009
9. HealthSouth Issues Preliminary Comments on the Presidents Healthcare Budget Proposal and Announces Plans to Host a Conference Call
10. PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results
11. NBTY Announces Preliminary Unaudited Net Sales Results for January 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: